Literature DB >> 9518455

Recombinant production of cyanovirin-N, a potent human immunodeficiency virus-inactivating protein derived from a cultured cyanobacterium.

T Mori1, K R Gustafson, L K Pannell, R H Shoemaker, L Wu, J B McMahon, M R Boyd.   

Abstract

Here we describe the recombinant production and purification of a novel anti-human immunodeficiency virus (HIV) protein, cyanovirin-N (CV-N), in Escherichia coli. Initial attempts to express CV-N using a vector containing an ompA signal peptide sequence resulted in production of an intractable mixture of the full-length (101 amino acid residue) protein and a truncated form lacking the first two N-terminal amino acids. The truncated protein was observed regardless of the host cell line, culture conditions, or induction time. These observations suggested that an as yet unidentified protease or peptidase was responsible for proteolytic cleavage between the second and third N-terminal amino acids of CV-N when presented as an ompA-CV-N fusion protein. When the ompA signal peptide sequence was replaced by a pelB signal peptide sequence, CV-N was produced in high yield as a single, homogeneous protein. This was confirmed by electrospray ionization mass spectrometry and N-terminal sequencing. This expression system provides a basis for large-scale production of clinical grade CV-N for further research and development as an anti-HIV microbicide.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9518455     DOI: 10.1006/prep.1997.0838

Source DB:  PubMed          Journal:  Protein Expr Purif        ISSN: 1046-5928            Impact factor:   1.650


  17 in total

1.  Multiple antiviral activities of cyanovirin-N: blocking of human immunodeficiency virus type 1 gp120 interaction with CD4 and coreceptor and inhibition of diverse enveloped viruses.

Authors:  B Dey; D L Lerner; P Lusso; M R Boyd; J H Elder; E A Berger
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

2.  Human Immunodeficiency Virus (HIV) Separation and Enrichment via the Combination of Antiviral Lectin Recognition and a Thermoresponsive Reagent System.

Authors:  Joseph C Phan; Barrett J Nehilla; Selvi Srinivasan; Robert W Coombs; Kim A Woodrow; James J Lai
Journal:  Pharm Res       Date:  2016-07-11       Impact factor: 4.200

3.  Rational and computational design of stabilized variants of cyanovirin-N that retain affinity and specificity for glycan ligands.

Authors:  Vadim Patsalo; Daniel P Raleigh; David F Green
Journal:  Biochemistry       Date:  2011-11-16       Impact factor: 3.162

4.  Cyanovirin-N binds to gp120 to interfere with CD4-dependent human immunodeficiency virus type 1 virion binding, fusion, and infectivity but does not affect the CD4 binding site on gp120 or soluble CD4-induced conformational changes in gp120.

Authors:  M T Esser; T Mori; I Mondor; Q J Sattentau; B Dey; E A Berger; M R Boyd; J D Lifson
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

5.  Antiviral activity of recombinant cyanovirin-N against HSV-1.

Authors:  Hong Yu; Zong-tao Liu; Rui Lv; Wen-qing Zhang
Journal:  Virol Sin       Date:  2010-12-21       Impact factor: 4.327

6.  Cyanovirin-N, a potent human immunodeficiency virus-inactivating protein, blocks both CD4-dependent and CD4-independent binding of soluble gp120 (sgp120) to target cells, inhibits sCD4-induced binding of sgp120 to cell-associated CXCR4, and dissociates bound sgp120 from target cells.

Authors:  T Mori; M R Boyd
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

7.  Resistance of human immunodeficiency virus type 1 to the high-mannose binding agents cyanovirin N and concanavalin A.

Authors:  Myriam Witvrouw; Valery Fikkert; Anke Hantson; Christophe Pannecouque; Barry R O'keefe; James McMahon; Leonidas Stamatatos; Erik de Clercq; Anders Bolmstedt
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

8.  Potent anti-influenza activity of cyanovirin-N and interactions with viral hemagglutinin.

Authors:  Barry R O'Keefe; Donald F Smee; Jim A Turpin; Carrie J Saucedo; Kirk R Gustafson; Toshiyuki Mori; Dennis Blakeslee; Robert Buckheit; Michael R Boyd
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

9.  Treatment of influenza A (H1N1) virus infections in mice and ferrets with cyanovirin-N.

Authors:  Donald F Smee; Kevin W Bailey; Min-Hui Wong; Barry R O'Keefe; Kirk R Gustafson; Vasiliy P Mishin; Larisa V Gubareva
Journal:  Antiviral Res       Date:  2008-07-02       Impact factor: 5.970

10.  Cyanovirin-N produced in rice endosperm offers effective pre-exposure prophylaxis against HIV-1BaL infection in vitro.

Authors:  E Vamvaka; A Evans; K Ramessar; L R H Krumpe; R J Shattock; B R O'Keefe; P Christou; T Capell
Journal:  Plant Cell Rep       Date:  2016-03-23       Impact factor: 4.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.